Castle Biosciences (CSTL) Stock Price, News & Analysis

Company Overview

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Key Stats

• Today's Range: $20.35 to $21.50
• 50-Day Range: $14.65 to $20.84
• 52-Week Range: $14.59 to $35.84
• Volume: 92,252 shs
• Average Volume: 473,263 shs
• Market Capitalization: $622.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.00
• Consensus Rating: Buy

Castle Biosciences Stock Analysis - MarketRank™

Castle Biosciences scored higher than 49% of companies evaluated by MarketBeat, and ranked 563rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Castle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Castle Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Castle Biosciences are expected to decrease in the coming year, from $0.44 to ($1.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Castle Biosciences is -61.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Castle Biosciences is -61.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Castle Biosciences has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.16% of the float of Castle Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Castle Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Castle Biosciences has recently decreased by 0.71%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Castle Biosciences does not currently pay a dividend.

Dividend Growth

Castle Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.16% of the float of Castle Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Castle Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Castle Biosciences has recently decreased by 0.71%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.78

News Sentiment

Castle Biosciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Castle Biosciences this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for CSTL on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Castle Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.50% of the stock of Castle Biosciences is held by insiders.

Percentage Held by Institutions

92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CSTL Stock Analysis - Frequently Asked Questions

How have CSTL shares performed this year?

Castle Biosciences' stock was trading at $26.65 on January 1st, 2025. Since then, CSTL stock has decreased by 19.5% and is now trading at $21.46.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its quarterly earnings data on Monday, August, 4th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.51) by $0.66. The company had revenue of $86.18 million for the quarter, compared to analyst estimates of $71.53 million. Castle Biosciences had a negative net margin of 2.73% and a positive trailing twelve-month return on equity of 2.37%.
Read the conference call transcript.

When did Castle Biosciences IPO?

Castle Biosciences (CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Castle Biosciences' major shareholders?

Top institutional investors of Castle Biosciences include Wasatch Advisors LP (3.62%), Braidwell LP (2.84%), Allianz Asset Management GmbH (2.47%) and Geode Capital Management LLC (2.38%). Insiders that own company stock include Kristen M Oelschlager, Derek J Maetzold, Tobin W Juvenal, Frank Stokes, Ellen Goldberg, Tiffany Olson and Daniel Bradbury.
View institutional ownership trends.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Castle Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), PayPal (PYPL), Adobe (ADBE), Advanced Micro Devices (AMD) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 8/26/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CSTL
• CIK: 1447362
• Web: castlebiosciences.com
• Phone: (866) 788-9007
• Fax: N/A
• Employees: 540
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Castle Biosciences: $37.00
• High Price Target: $41.00
• Low Price Target: $30.00
• Potential Upside/Downside: +72.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 48.77
• P/E Growth: N/A
• Net Income: $18.25 million
• Net Margins: -2.73%
• Pretax Margin: -2.96%
• Return on Equity: 2.37%
• Return on Assets: 2.03%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 6.85
• Quick Ratio: 6.69

Sales & Book Value

• Annual Sales: $346.27 million
• Price / Sales: 1.80
• Cash Flow: $1.01 per share
• Price / Cash Flow: 21.18
• Book Value: $16.28 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 29,008,000
• Free Float: 26,919,000
• Market Cap: $622.51 million
• Optionable: Optionable
• Beta: 1.09